NASDAQ:SCPH - Scpharmaceuticals Stock Price, Forecast & News

Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Scpharmaceuticals Inc (NASDAQ:SCPH) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.12. View Scpharmaceuticals' Earnings History.

Scpharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Scpharmaceuticals.

1 equities research analysts have issued twelve-month price objectives for Scpharmaceuticals' shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate Scpharmaceuticals' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 47.9% from the stock's current price. View Analyst Price Targets for Scpharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scpharmaceuticals.

Headlines about SCPH stock have been trending very positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Scpharmaceuticals earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View News Stories for Scpharmaceuticals.

Scpharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 20,200 shares, an increase of 43.3% from the January 15th total of 14,100 shares. Based on an average daily trading volume, of 45,900 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the shares of the stock are sold short. View Scpharmaceuticals' Current Options Chain.

Some companies that are related to Scpharmaceuticals include Basilea Pharmaceutica (BPMUF), Kadmon (KDMN), Flexion Therapeutics (FLXN), Urogen Pharma (URGN), Phoenix Tree (IMAB), Atreca (BCEL), XBiotech (XBIT), ZIOPHARM Oncology (ZIOP), AC Immune (ACIU), Kura Oncology (KURA), Assembly Biosciences (ASMB), Molecular Templates (MTEM), Crinetics Pharmaceuticals (CRNX), Neoleukin Therapeutics (NLTX) and Ardelyx (ARDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Scpharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Melinta Therapeutics (MLNT), Selecta Biosciences (SELB), Omeros (OMER), Progenics Pharmaceuticals (PGNX), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), Clearside Biomedical (CLSD), Catalyst Pharmaceuticals (CPRX) and Dynavax Technologies (DVAX).

(SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Scpharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include 5AM Venture Management LLC (17.46%), Renaissance Technologies LLC (0.88%), Alambic Investment Management L.P. (0.27%) and Jacobs Levy Equity Management Inc. (0.10%). Company insiders that own Scpharmaceuticals stock include John H Tucker and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Scpharmaceuticals.

SCPH stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P.. View Insider Buying and Selling for Scpharmaceuticals.

SCPH stock was purchased by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Renaissance Technologies LLC and Jacobs Levy Equity Management Inc.. Company insiders that have bought Scpharmaceuticals stock in the last two years include John H Tucker and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Scpharmaceuticals.

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SCPH stock can currently be purchased for approximately $8.79.

Scpharmaceuticals has a market capitalization of $163.71 million. The company earns $-29,440,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe.View Additional Information About Scpharmaceuticals.

The official website for Scpharmaceuticals is http://www.scpharma.com/.

Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]